Translating insights into therapies for Long Covid DOI Open Access
Annukka A.R. Antar, Andrea L. Cox

Science Translational Medicine, Год журнала: 2024, Номер 16(773)

Опубликована: Ноя. 13, 2024

Long Covid is defined by a wide range of symptoms that persist after the acute phase severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Commonly reported include fatigue, weakness, postexertional malaise, and cognitive dysfunction, with many other reported. Symptom range, duration, severity are highly variable partially overlap myalgic encephalomyelitis/chronic fatigue post-acute infectious syndromes, highlighting opportunities to define shared mechanisms pathogenesis. Potential diverse, including persistence viral reservoirs, dysregulated immune responses, direct damage tissues targeted SARS-CoV-2, inflammation driven reactivation latent infections, vascular endothelium activation or subsequent thromboinflammation, autoimmunity, metabolic derangements, microglial activation, microbiota dysbiosis. The heterogeneity baseline characteristics people Covid, as well varying states immunity therapies given at time infection, have made etiologies difficult determine. Here, we examine progress on preclinical models for review being in clinical trials, need large human studies further development better understand Covid. Such will inform trials treatments benefit those living this condition.

Язык: Английский

Animal models of post-acute COVID-19 syndrome: a call for longitudinal animal studies DOI Creative Commons

Jingyi Dai,

Feihong HE,

Qian Chen

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 26, 2025

Animal models are indispensable for unraveling the mechanisms underlying post-acute sequelae of COVID-19 (PASC). This review evaluates recent research on PASC-related perturbations in animal models, drawing comparisons with clinical findings. Despite limited number studies post-COVID conditions, particularly those extending beyond three months, these provide valuable insights. Three hallmark features PASC-lung fibrosis, hyperglycemia, and neurological sequelae-have been successfully replicated paving way mechanistic discoveries future medical interventions. Although most have reported conditions within 14-60 days post-infection, they still offer critical reference long-term research. also explores potential persisting immune misfiring, a key factor chronicity PASC symptoms. Moreover, challenges modeling discussed, including genetic diversity inbred strains difficulties accurately identifying PASC-affected individuals. To address issues, we propose methodological improvements, such as comparing individual parameters control averages incorporating genetically diverse populations like collaborative cross models. These strategies will enhance identification characterization endotypes studies. By integrating findings from manifestations PASC, can more insights into its support development effective therapeutic strategies. Finally, emphasize urgent need longitudinal to fully uncover driving guide interventions mitigate public health impact.

Язык: Английский

Процитировано

0

Translating insights into therapies for Long Covid DOI Open Access
Annukka A.R. Antar, Andrea L. Cox

Science Translational Medicine, Год журнала: 2024, Номер 16(773)

Опубликована: Ноя. 13, 2024

Long Covid is defined by a wide range of symptoms that persist after the acute phase severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Commonly reported include fatigue, weakness, postexertional malaise, and cognitive dysfunction, with many other reported. Symptom range, duration, severity are highly variable partially overlap myalgic encephalomyelitis/chronic fatigue post-acute infectious syndromes, highlighting opportunities to define shared mechanisms pathogenesis. Potential diverse, including persistence viral reservoirs, dysregulated immune responses, direct damage tissues targeted SARS-CoV-2, inflammation driven reactivation latent infections, vascular endothelium activation or subsequent thromboinflammation, autoimmunity, metabolic derangements, microglial activation, microbiota dysbiosis. The heterogeneity baseline characteristics people Covid, as well varying states immunity therapies given at time infection, have made etiologies difficult determine. Here, we examine progress on preclinical models for review being in clinical trials, need large human studies further development better understand Covid. Such will inform trials treatments benefit those living this condition.

Язык: Английский

Процитировано

4